Voyager Therapeutics and AbbVie have agreed to broaden their existing gene therapy pact to incorporate Parkinson’s and other neurodegenerative diseases. Voyager will carry out development of viral vectors for the production of antibodies to target alpha-synuclein, a protein which builds up in the brain and is linked to diseases such as Parkinson’s. It will also take on gene therapy research up to Phase 1, at which point AbbVie can license the programme for further development and possible commercialisation. Voyager will receive a fee from AbbVie of $245m, with potential for $65m in option payments and $728m in milestone payments.
Voyager Therapeutics and AbbVie have agreed to broaden their existing gene therapy pact to incorporate Parkinson’s and other neurodegenerative diseases. Voyager will carry out development of viral vectors for the production of antibodies to target alpha-synuclein, a protein which builds up in the brain and is linked to diseases such as Parkinson’s. It will also take on gene therapy research up to Phase 1, at which point AbbVie can license the programme for further development and possible commercialisation. Voyager will receive a fee from AbbVie of $65m, with potential for $245m in option payments and $728m in milestone payments.